Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures

@article{Messori2015AchievingSV,
  title={Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures},
  author={Andrea Messori and Brigitta Badiani and Sabrina Trippoli},
  journal={Clinical Drug Investigation},
  year={2015},
  volume={35},
  pages={843-850}
}
Background and ObjectivesWe studied the effect of achieving sustained virological response (SVR) on the risk of developing hepatocellular carcinoma (HCC) in patients with hepatitis C receiving anti-hepatitis C virus treatment. Avoiding HCC is considered the main long-term benefit of successful antiviral treatment.MethodsOur literature search extended up to June 2015. We identified all studies that assessed the risk of HCC in patients achieving or not achieving SVR. Meta-analysis was based on a… Expand
Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
TLDR
SVR after interferon-based treatment substantially reduces but does not eliminate HCC risk, which is markedly higher among those with cirrhosis and age ⩾50years at treatment initiation, which will warrant continued surveillance for HCC post-SVR. Expand
Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis
TLDR
Achieving sustained virological response (SVR) with an all-oral DAA regimen during follow-up was independently associated with a lower risk of HCC emergence, and this was a multicentre prospective cohort study recruiting HIV/HCV-coinfected patients with new diagnosis of compensated cirrhosis. Expand
Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma.
TLDR
Recurrence of HCC remains a threat in HCV patients even after achieving an SVR, and implementation of long-term surveillance programs is highly recommended. Expand
Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes
TLDR
It is hypothesized that the benefits from SVR occur largely due to regression of fibrosis, which arises from the halt on the fibrogenic stimuli and activation of extracellular matrix reabsorption signals. Expand
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
  • E. Gane, F. Poordad, +17 authors F. Mensa
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
TLDR
G/P was safe and efficacious in patients with compensated liver disease, including those with CKD 4/5, and PK analysis demonstrated a 2.2-fold increase in glecaprevir exposure, but not pibrentasvir exposure, in Patients with compensated cirrhosis. Expand
A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma
TLDR
An easy and practical model score may be an auxiliary tool for identification of HCV patients with low probability of small diameter HCC at initial evaluation composed of three serum examinations used in routine outpatient clinical practice. Expand
Role of assessing liver fibrosis in management of chronic hepatitis C virus infection.
TLDR
Fibrosis regression has been demonstrated after the eradication of hepatitis C virus infection and is associated with a lower risk of hepatic cirrhosis and liver cancer, however, patients showing advanced fibrosis and Cirrhosis must be followed-up after SVR, as risks of portal hypertension and HCC remain. Expand
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
TLDR
Glecaprevir/pibrentasvir was highly efficacious and well tolerated in HCV treatment-naïve patients with APRI ≤ 1 and no prior evidence of cirrhosis. Expand
Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
TLDR
8-week G/P treatment is safe and efficacious in DAA-naive patients without cirrhosis and with HCV GT1 or GT2 infection, demonstrating high SVR12 rates regardless of baseline patient and disease characteristics. Expand
Management of the patient with SVR.
TLDR
To maximize the health benefits of SVR, counseling patients on best means to maintain good liver health and prevent reinfection are also important. Expand
...
1
2
...

References

SHOWING 1-10 OF 40 REFERENCES
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.
TLDR
In patients with HCV-related cirrhosis, SVR is associated with a significant decrease in the incidence of HCC and mortality during a follow-up period of 7.7 years, which is a strong argument to perform and repeat antiviral treatments in patients with compensated Cirrhosis. Expand
Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis
TLDR
In compensated HCV-related cirrhosis, SVR markedly reduces the risk of HCC and improves survival, and clearance of the virus should be intensively attempted in these patients. Expand
Long‐term effect of interferon alpha‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis
TLDR
The results suggest that achieving SVR by IFN alpha‐2b plus ribavirin therapy may decrease the incidence of HCC in patients with HCV‐related cirrhosis. Expand
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
TLDR
In conclusion, antiviral therapy for NALT patients with HCV infection can lower the HCC incidence in responders, particularly for aged and male patients. Expand
Outcome of sustained virological responders with histologically advanced chronic hepatitis C
TLDR
Patients with advanced chronic hepatitis C who achieved SVR had a marked reduction in death/liver transplantation, and in liver‐related morbidity/mortality, although they remain at risk for HCC. Expand
Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study
TLDR
In patients with HCV‐related, histologically proven cirrhosis, achievement of a SVR after IFNα therapy was associated with a reduction of liver‐related mortality lowering both the risk of complications and HCC development. Expand
Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study
TLDR
Among non-SVR patients, a decrease in the AFP integration value by interferon therapy closely correlates with reduced risk of HCC incidence after treatment, which is significant compared to patients with average AFP integration values of ≥10 ng/mL. Expand
Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients.
  • T. Okanoue, Y. Itoh, +5 authors M. Minami
  • Medicine
  • Hepatology research : the official journal of the Japan Society of Hepatology
  • 2002
TLDR
IFN therapy lowers the rate of the progression of HCC and improves the long-term survival even in CH-C patients who transiently respond to IFN therapy. Expand
Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications
TLDR
Long‐term follow up of HCV patients indicates that virological response persists over time and is associated with a very low incidence of liver complications. Expand
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
TLDR
SVR has a strong independent positive influence on the incidence of HCC and on the prognosis of these patients and is achieved in one-third of patients with HCV-related cirrhosis treated with peginterferon and ribavirin. Expand
...
1
2
3
4
...